Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2-Breast cancer: A network meta-analysis of 19 RCTs-MedSci.cn - 梅斯（MedSci）

Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2-Breast cancer: A network meta-analysis of 19 RCTs

Wang, LD; Da, H; Li, XL; Ran, XH; Wu, W; Sheng, ZX

Sheng, ZX (corresponding author), Weifang Peoples Hosp, Dept Hematol, Weifang, Shandong, Peoples R China.

BREAST JOURNAL, 2020; 26 (9): 1862

科室
- - 订阅+
  - 更多科室
工具
服务